Reverse Payment Settlement Agreements in the Pharmaceutical Industry: State of Play and Possible Developments in the US and the EU

• Diletta Danieli ^[1]
  1. [1] University of Verona

     University of Verona

     Verona, Italia

     
• Localización: Rivista di diritto internazionale privato e processuale, ISSN 0035-6174, Vol. 52, Nº. 1, 2016, págs. 106-140
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The aim of this paper is to analyse the issue of reverse payment agreements concluded in a context of patent litigation between brand pharmaceutical companies and generic manufacturers. Such topic is addressed from both US an EU perspectives: after an introduction on the relevant legislative framework in these two legal system, the paper focuses on the case law of the US Supreme Court (Actavis case), the European Commission and the General Court (Lundbeck, Johnson&Johnson and Novartis, Servier cases). Taking into account the opinions expressed in these decisions, an assessment of possible future developments is offered, with particular regard to the lagal standard adopted to evaluate the exercise of patent rights in relation to competition law.